Why did Acad drop so much?
Sophia Dalton
Updated on February 07, 2026
Why did Acad drop so much?
ACAD stock has had a volatile ride the past few months. However, over the recent weeks, the stock has plummeted to levels of $27 currently. The recent drop can be attributed to the U.S. FDA finding deficiencies in its application for its psychosis drug – Nuplazid.
Is Acad a good buy?
We believe that ACADIA Pharmaceuticals stock (NASDAQ NDAQ +0.6% : ACAD), a biopharmaceutical company focused on neuroscience drugs, is a good buying opportunity at the present time. However, over the recent weeks, the stock has plummeted to levels of $27 currently.
What is Acad pharmaceuticals?
The Company is a biopharmaceutical company focused on the discovery, development, and commercialization of small molecule drugs for the treatment of central nervous system disorders.
Where is Acadia Pharmaceuticals located?
San Diego
ACADIA’s headquarters are located in San Diego, California, and it maintain research and development operations in both San Diego and Malmo, Sweden.
Will Acad stock go up?
Will Acadia Pharmaceuticals stock price grow / rise / go up? Yes. The ACAD stock price can go up from 18.480 USD to 25.596 USD in one year.
Is Acad a buy or sell?
ACADIA Pharmaceuticals has received a consensus rating of Hold. The company’s average rating score is 2.33, and is based on 6 buy ratings, 12 hold ratings, and no sell ratings.
Will Acadia Pharmaceuticals stock go up?
Will Acadia Pharmaceuticals stock price grow / rise / go up? Yes. The ACAD stock price can go up from 16.615 USD to 21.018 USD in one year.
How many employees does Acadia Pharmaceuticals have?
Acadia Pharmaceuticals
| Formerly | Receptor Technologies |
|---|---|
| Total equity | US$699.14 million (2019) |
| Number of employees | 570 (June 30, 2020) |
| Website | acadia-pharm.com |
| Footnotes / references |
What drugs does Acadia make?
Nuplazid® – Acadia. NUPLAZID® (pimavanserin) is the first and only medication approved by the U.S. Food and Drug Administration (FDA) for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis (PDP).
Is Ayx stock a buy?
The Bottom Line on AYX Stock And that’s why we’d recommend buying on the dip, since AYX stock is currently very undervalued and has solid upside potential. Many of the stocks I cover in my premium newsletter advisory service, Innovation Investor, are as exciting or more exciting than TK stock.
Who manufactures Nuplazid?
Nuplazid is marketed by Acadia Pharmaceuticals Inc. of San Diego, California.
Show less
The ACADIA Pharmaceuticals 52-week low stock price is 19.20, which is 30% below the current share price. The average ACADIA Pharmaceuticals stock price for the last 52 weeks is 41.06.
What is the purpose of the company Acadia?
Acadia is trailblazing breakthroughs in neuroscience to elevate life. We are at the forefront of healthcare, fighting for breakthroughs in our science, our therapies and the way we work, but also in the lives of the people we serve. At Acadia, we are committed to our purpose: we fight disease so more you shines through.
What is the hold rating on ACAD pharmaceuticals?
A hold rating indicates that analysts believe investors should maintain any existing positions they have in ACAD, but not buy additional shares or sell existing shares. View analyst ratings for ACADIA Pharmaceuticals or view top-rated stocks.
Who are the major holders of Acad stock?
ACAD stock was purchased by a variety of institutional investors in the last quarter, including Perceptive Advisors LLC, Ameriprise Financial Inc., Federated Hermes Inc., Voloridge Investment Management LLC, Price T Rowe Associates Inc. MD, Renaissance Technologies LLC, Fred Alger Management LLC, and Woodline Partners LP.
What is the stock price of Acadia Pharmaceuticals?
ACADIA Pharmaceuticals’ stock was trading at $36.87 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, ACAD shares have increased by 16.1% and is now trading at $42.79. View which stocks have been most impacted by Coronavirus.
A hold rating indicates that analysts believe investors should maintain any existing positions they have in ACAD, but not buy additional shares or sell existing shares. View analyst ratings for ACADIA Pharmaceuticals or view top-rated stocks.
ACAD stock was purchased by a variety of institutional investors in the last quarter, including Perceptive Advisors LLC, Ameriprise Financial Inc., Federated Hermes Inc., Voloridge Investment Management LLC, Price T Rowe Associates Inc. MD, Renaissance Technologies LLC, Fred Alger Management LLC, and Woodline Partners LP.
Are there class action lawsuits against Acadia Pharmaceuticals?
NEW YORK, NY / ACCESSWIRE / June 7, 2021 / The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. There is no cost to participate in the suit.
